Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro
- PMID: 16510483
- DOI: 10.1177/0269881106063273
Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro
Abstract
There is much evidence from animal studies that the recreational drug MDMA is a selective toxin which damages serotonin nerve terminals and axons. These in vivo studies show that an interaction between MDMA and the serotonin transporter protein (SERT) is the .rst step in toxicity. To further our understanding of the biochemical processes of MDMA toxicity we wished to use an in vitro model for toxicity. We produced two COS-7 cell lines with different levels of expression of recombinant rat SERT, as determined by 5-HT uptake assays, and compared them to human SERT expressing JAR cells and to untransfected COS-7 cells which do not express SERT. Cultured cells were exposed to MDMA (0.1 microM-1 mM) for 24 or 48 h at 37 degrees C before assessing cytotoxicity by LDH release and MTT turnover. Only at the highest concentration used, 1 mM, was MDMA cytotoxic, and this toxicity was found in all cell lines. Cytotoxicity caused by 48 h exposure to 1 mM MDMA at 37 degrees C was not related to the level of SERT expression, not blocked by the SERT-blocking drugs paroxetine or fluoxetine and not enhanced, in JAR cells, by forskolin preincubation that increased 5-HT uptake capacity by 50%. We conclude that SERT expression is not sufficient to confer MDMA toxicity to cell lines. Therefore SERT-expressing cell lines do not offer a simple model system to elucidate the mechanisms underlying MDMA toxicity.
Similar articles
-
Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethamphetamine (MDMA) under acidic conditions.Neurosci Lett. 2007 Nov 27;428(2-3):72-6. doi: 10.1016/j.neulet.2007.09.037. Epub 2007 Sep 26. Neurosci Lett. 2007. PMID: 17949903
-
Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.J Psychopharmacol. 2006 Mar;20(2):211-25. doi: 10.1177/0269881106059486. J Psychopharmacol. 2006. PMID: 16510479 Review.
-
3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.Synapse. 2004 Sep 15;53(4):240-8. doi: 10.1002/syn.20058. Synapse. 2004. PMID: 15266556
-
Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan.Neuroscience. 2007 Aug 10;148(1):212-20. doi: 10.1016/j.neuroscience.2007.05.024. Epub 2007 Jul 12. Neuroscience. 2007. PMID: 17629409
-
Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.J Psychopharmacol. 2006 Mar;20(2):164-75. doi: 10.1177/0269881106061515. J Psychopharmacol. 2006. PMID: 16510475 Review.
Cited by
-
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death.Invest New Drugs. 2012 Aug;30(4):1471-83. doi: 10.1007/s10637-011-9730-5. Epub 2011 Aug 18. Invest New Drugs. 2012. PMID: 21850491
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical